Profile data is unavailable for this security.
About the company
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
- Revenue in USD (TTM)812.04m
- Net income in USD-212.62m
- Incorporated2018
- Employees2.65k
- LocationTilray Brands Inc655 Madison Avenue, 19Th FloorNEW YORK 10065United StatesUSA
- Phone+1 (416) 934-2141
- Fax+1 (416) 934-2141
- Websitehttps://www.tilray.com/
More ▼
Mergers & acquisitions
| Acquired company | TLRY:NSQ since announced | Transaction value |
|---|---|---|
| Revolver Brewing LLC | -17.42% | -- |
| Terrapin Beer Co | -17.42% | -- |
| Hop Valley Brewing Co | -17.42% | -- |
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacira Biosciences Inc | 694.96m | -90.73m | 775.71m | 711.00 | -- | 1.03 | -- | 1.12 | -2.15 | -2.15 | 13.03 | 16.24 | 0.4548 | 1.71 | 7.03 | 977,436.00 | -5.94 | 3.35 | -6.83 | 3.98 | 74.35 | 72.63 | -13.06 | 8.57 | 1.89 | -- | 0.4393 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Avid Bioservices Inc | 142.36m | -144.17m | 780.21m | 371.00 | -- | 13.31 | -- | 5.48 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
| Evolus Inc | 248.33m | -55.46m | 787.72m | 322.00 | -- | 133.59 | -- | 3.17 | -0.9141 | -0.9141 | 4.11 | 0.0931 | 1.25 | 4.59 | 6.61 | 909,619.10 | -27.90 | -40.92 | -38.48 | -59.74 | 69.94 | 65.43 | -22.33 | -80.46 | 2.23 | -2.04 | 0.9537 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Pliant Therapeutics Inc | 0.00 | -201.68m | 840.28m | 158.00 | -- | 2.43 | -- | -- | -3.34 | -3.34 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -40.90 | -33.24 | -43.90 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0802 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Liquidia Corp | 14.84m | -112.11m | 892.91m | 136.00 | -- | 12.95 | -- | 60.17 | -1.57 | -1.57 | 0.2102 | 0.8208 | 0.0993 | -- | 4.04 | 109,117.60 | -75.00 | -55.02 | -87.85 | -62.69 | 69.52 | 82.18 | -755.46 | -474.59 | 5.78 | -29.47 | 0.578 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Collegium Pharmaceutical Inc | 599.25m | 88.59m | 1.01bn | 197.00 | 15.71 | 4.32 | 4.27 | 1.69 | 2.00 | 2.00 | 13.05 | 7.27 | 0.4261 | 6.25 | 2.92 | 3,041,853.00 | 6.30 | 2.79 | 9.38 | 4.80 | 62.36 | 50.88 | 14.78 | 5.16 | 0.8832 | 3.94 | 0.7873 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Phibro Animal Health Corp | 1.05bn | 17.41m | 1.02bn | 1.94k | 58.38 | 3.93 | 18.90 | 0.9697 | 0.4293 | 0.4293 | 25.82 | 6.38 | 1.08 | 2.60 | 6.75 | 539,568.10 | 1.80 | 3.93 | 2.20 | 4.90 | 31.47 | 31.18 | 1.66 | 3.77 | 1.69 | 2.20 | 0.6472 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Avadel Pharmaceuticals PLC (ADR) | 95.15m | -106.22m | 1.27bn | 154.00 | -- | 18.00 | -- | 13.31 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Innoviva Inc | 352.75m | 64.59m | 1.27bn | 112.00 | 29.54 | 1.90 | 12.18 | 3.61 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| ANI Pharmaceuticals Inc | 555.46m | -8.77m | 1.28bn | 642.00 | -- | 3.17 | 24.86 | 2.31 | -0.4489 | -0.4489 | 28.67 | 20.44 | 0.5102 | 1.75 | 2.96 | 865,196.30 | -0.6514 | -2.83 | -0.7654 | -3.35 | 59.79 | 60.18 | -1.28 | -6.15 | 1.97 | 0.7018 | 0.5921 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Tilray Brands Inc | 812.04m | -212.62m | 1.33bn | 2.65k | -- | 0.37 | -- | 1.64 | -0.2746 | -0.2746 | 1.03 | 3.97 | 0.1875 | 2.31 | 8.73 | 306,429.10 | -4.64 | -- | -5.15 | -- | 29.42 | -- | -24.78 | -- | 1.57 | -1.16 | 0.0953 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.65bn | 267.00 | -- | 4.37 | -- | 27.05 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.69bn | 497.00 | -- | 4.70 | -- | 6.00 | -1.07 | -1.07 | 5.55 | 7.18 | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Harrow Inc | 154.15m | -33.58m | 1.77bn | 315.00 | -- | 30.25 | -- | 11.49 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Tarsus Pharmaceuticals Inc | 83.37m | -150.07m | 1.81bn | 244.00 | -- | 7.17 | -- | 21.71 | -4.43 | -4.43 | 2.43 | 6.63 | 0.2947 | -- | 5.36 | 341,696.70 | -53.05 | -31.56 | -60.10 | -33.82 | 92.50 | -- | -180.00 | -242.59 | 6.99 | -- | 0.221 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Data as of Nov 12 2024. Currency figures normalised to Tilray Brands Inc's reporting currency: US Dollar USD
4.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tidal Investments LLCas of 30 Jun 2024 | 11.01m | 1.26% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 8.37m | 0.96% |
| Highbridge Capital Management LLCas of 30 Sep 2024 | 5.19m | 0.59% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 3.28m | 0.38% |
| Global X Investments Canada, Inc.as of 30 Sep 2024 | 3.27m | 0.37% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.00m | 0.34% |
| Aristeia Capital LLCas of 30 Jun 2024 | 2.44m | 0.28% |
| HRT Financial LP (US)as of 30 Jun 2024 | 2.15m | 0.25% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.09m | 0.24% |
| BMO Asset Management, Inc.as of 30 Jun 2024 | 2.08m | 0.24% |
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
